Drugs / MEN1703
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06534437 | Dec 2024 → Dec 2026 expected | aggressive B-cell non-Hodgkin lymphoma | Ryvu Therapeutics SA | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 18
| Date | Issuer | Release |
|---|---|---|
| 2024-04-10 | Ryvu Therapeutics SA | Results Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting ryvu.com ↗
MEN1703 (SEL24), presented by partner Menarini Group, shows cytotoxic activity in myelofibrosis cell lines as a monotherapy and synergistically in combination with ruxolitinib. |
| 2024-03-06 | Ryvu Therapeutics SA | Results Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting ryvu.com ↗
Ryvu’s partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib. |
| 2023-10-16 | Ryvu Therapeutics SA | Results Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ryvu.com ↗
Ryvu’s partner Menarini presented preclinical data on MEN1703 (SEL24) showing promising anti-tumor activity in B-cell lymphomas, supporting the Phase II clinical program |
| 2023-10-04 | Ryvu Therapeutics SA | Results Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ryvu.com ↗
Ryvu licensee, Menarini Group, and academic collaborators will present preclinical data on MEN1703 (SEL24), a first-in-class, oral, dual type I PIM/FLT3 inhibitor. |
| 2022-12-11 | Ryvu Therapeutics SA | Results Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting ryvu.com ↗
Preclinical Antitumor Activity of SEL24 (MEN1703) demonstrated in multiple myeloma (MM), Hodgkin’s lymphoma (HL), and diffuse large B-cell lymphoma (DLBCL) as well as in AML in combination with gilteritinib |
| 2022-11-03 | Ryvu Therapeutics SA | Results Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting ryvu.com ↗
Preclinical Models Show Potential for Clinical Efficacy of SEL24 (MEN1703) in multiple myeloma (MM), Hodgkin’s lymphoma (HL), and diffuse large B-cell lymphoma (DLBCL) |
| 2021-12-13 | Ryvu Therapeutics SA | Results Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium ryvu.com ↗
today announced updated clinical and preclinical data demonstrating the single-agent activity of its two lead oncology drug candidates, RVU120 and SEL24 (MEN1703) at the 63rd American Society of Hematology Annual Meeting, held December 11 – December 14, 2021, in Atlanta, as well as at the 44th Annual San Antonio Breast Cancer Symposium (SABCS) held December 7 – December 10, 2021. |
| 2021-11-04 | Menarini Group | Regulatory Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia menarini.com ↗
The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). |
| 2021-06-11 | Ryvu Therapeutics SA | Results Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini. ryvu.com ↗
Three out of five AML patients harboring IDH mutations treated at 75-125 mg achieved CR/CRi |
| 2021-06-01 | Menarini Group | Results Menarini Announces New SEL24/MEN1703 Clinical Data from DIAMOND-01 Trial menarini.com ↗
Data reported in the ASCO and EHA posters refer to patients enrolled in the Phase II, cohort expansion part of the study, which confirmed the manageable safety profile of the drug at the RD and showed preliminary single agent efficacy in relapsed/refractory AML, particularly in patients with IDH mutant disease either naïve or previously exposed to IDH inhibitors. |
| 2021-06-01 | Ryvu Therapeutics SA | Results SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021 ryvu.com ↗
In the dose escalation part of DIAMOND-01 trial, SEL24(MEN1703) demonstrated a manageable safety profile up to the recommended dose (RD) of 125 mg/day, along with initial evidence of anti-leukemic activity in a single agent setting. |
| 2020-12-01 | Menarini Group | Results Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial menarini.com ↗
We are pleased with the preliminary, positive results observed with SEL24/MEN1703, a PIM/FLT3 inhibitor under investigation for the treatment of AML. |
| 2020-12-01 | Ryvu Therapeutics SA | Results Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting ryvu.com ↗
The positive preliminary data from the dose escalation phase of DIAMOND-01 trial shows a manageable safety profile, signs of efficacy and a meaningful target engagement in peripheral blood and bone marrow blast cells of AML patients treated with SEL24/MEN1703. |
| 2020-05-14 | Menarini Group | Results 25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703 menarini.com ↗
Initial evidence of single agent efficacy was observed with 1 CR and 1 CRi in elderly patients who had exhausted standard therapeutic options. |
| 2020-05-14 | Ryvu Therapeutics SA | Results Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress ryvu.com ↗
Initial evidence of single agent efficacy was observed with 1 CR and 1 CRi in elderly patients who had exhausted standard therapeutic options. |
| 2020-03-18 | Ryvu Therapeutics SA | Results Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia ryvu.com ↗
Phase I dose escalation study was successfully completed with the establishment of the recommended dose for Phase II studies of the drug. |
| 2018-04-26 | Ryvu Therapeutics SA | Results Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia ryvu.com ↗
In this publication, researchers demonstrate that BCR crosslinking, CD40 stimulation, and co-culture with stromal cells increased PIMs expression in CLL cells, indicating microenvironment-dependent PIMs regulation. |
| 2018-04-16 | Ryvu Therapeutics SA | Results Selvita publishes research results on SEL24 in Oncotarget ryvu.com ↗
The authors show that SEL24 specifically inhibits PIM- and FLT3-ITD- related pathways and exhibits significantly broader anti-tumor activity in AML models than selective FLT3-ITD or PIM inhibitors. |
All press releases naming this drug 30 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEN1703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06534437 ↗ |
| Action | Inhibit | “is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3)” NCT06534437 ↗ |
| Route | Oral | “will be given MEN1703 orally at a dose of 150 mg daily” NCT06534437 ↗ |